According to a study presented at the ESMO Congress immunoonkologicheskom 2017, a new connection can restore the immune response in patients with melanoma.
"Inhibitors of control points are standard immunotherapy for the treatment of metastatic melanoma, - says Dr. Sapna Patel, lead author, assistant of the Department of Medical Oncology, University of Texas. - However, many patients do not respond to therapy, since there myeloid suppressor cells. "
In animal studies omaveloksolon inhibited the suppressor cells and restores the immune activity. Suppressor cells derived from myeloid, nitrogenous produce radicals that modify the receptors on the tumor surface, to hide it from cytotoxic lymphocytes, which kill tumor cells. Omaveloksolon inhibits nitrogen radicals and restores antitumor immune system.
Scientists have investigated the safety and effectiveness omaveloksolona in combination with inhibitors of control points. The study included 30 patients with unresectable or metastatic melanoma . The overall incidence of an immune response was 57%. The average response time - 19 weeks. Serious side effects associated with omaveloksolonom, was not, and it is well tolerated in combination with ipilimumab or nivolumabom.
"The results indicate that omaveloksolon can overcome resistance to inhibitors of control points, - says Dr. Patel. - This is one of the first studies showing a significant response rate in patients with melanoma. Further studies to increase the dose, as well as translational tissue experiments to understand the effect of this combination therapy. "
Commenting on the study of ESMO, Dr. Olivier Michel, head of the analytical of personalized oncology at the University of Lausanne, Switzerland, says: "The new mechanism of action omaveloksona - blocking suppressor cells, which are known to suppress the immune response. In this study, it was tested in the new combination therapy of immunological cancer and found encouraging response rates when combined omaveloksolona and ipilimumab or nivolumaba. The combination was well tolerated and may affect some of the mechanisms of immunity. We need more information before we can make a final conclusion about whether there is such a new drug combination treatment of melanoma. "